KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Restructuring Costs (2016 - 2017)

Historic Restructuring Costs for Teva Pharmaceutical Industries (TEVA) over the last 6 years, with Q4 2016 value amounting to $91.0 million.

  • Teva Pharmaceutical Industries' Restructuring Costs rose 4677.42% to $91.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $104.2 billion, marking a year-over-year increase of 7019.02%. This contributed to the annual value of $91.0 million for FY2016, which is 4677.42% up from last year.
  • Teva Pharmaceutical Industries' Restructuring Costs amounted to $91.0 million in Q4 2016, which was up 4677.42% from $43.0 billion recorded in Q3 2016.
  • Teva Pharmaceutical Industries' 5-year Restructuring Costs high stood at $61.0 billion for Q3 2015, and its period low was $43.0 million during Q1 2013.
  • Moreover, its 4-year median value for Restructuring Costs was $85.5 million (2014), whereas its average is $13.1 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Restructuring Costs crashed by 3984.96% in 2014 and then skyrocketed by 4677.42% in 2016.
  • Over the past 4 years, Teva Pharmaceutical Industries' Restructuring Costs (Quarter) stood at $133.0 million in 2013, then plummeted by 39.85% to $80.0 million in 2014, then dropped by 22.5% to $62.0 million in 2015, then soared by 46.77% to $91.0 million in 2016.
  • Its Restructuring Costs was $91.0 million in Q4 2016, compared to $43.0 billion in Q3 2016 and $62.0 million in Q4 2015.